RE:RE:RE:not sure whyLongholder99 wrote: Exactly. Good riddance to Frost a d his warrants. I can wait a few more weeks happily knowing that a big load of leverage and shenanigans goes down the drain. I know it's pretty speculative to suspect this is the play. Who knows....maybe the money that came in in October is behind this tactic. I hope it is as we suspect and the news starts flowing soon after.
March proves up the 2nd treatment 'good for business model' and gives us our first legit 'stake/claim' of the 1.1b opportunity
As claridge said with the 200m deal worth 2b a 10x multiple 2b is $7 bucks roughly here.
Long time ago this board use to speak of getting 20% of said market..
Starters.
160m is Mackie .80 /200m
160m is Morningstar .54/300m (minus frost dilution after march high 270-80s?) .60+ ?
160m is Rogers 2014 Cambridge P1 Big pharma (now in 2020 inflation nees to be a recalc)
And I linked the Pre-FDA 65m + 60m Immunomedics Largest deal for a Single Lead Asset
Immunomedics The Largest Single-Asset License Agreement for Greater China To Date Provides Everest Medicines the Right to Develop and Commercialize Sacituzumab Govitecan for All Cancer Indications in Greater China, South Korea, and Certain ASEAN Countries
Immunomedics Will Receive Upfront Payment of $65 Million and an additional $60 Million based on U.S. FDA Approval of Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer, as well as Potential Development, Regulatory, and Sales Milestone Payments Totaling $710 Million and Escalating Tiered Royalties that Begin in the Mid-Teens on Net Sales within the Territory